{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:31:00Z","timestamp":1787020260309,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13071-2","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T09:03:02Z","timestamp":1729674182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["In-depth exploration of the focus issues of TKI combined with radiotherapy for EGFR-mutant lung adenocarcinoma patients with brain metastasis: a systematic analysis based on literature metrology, meta-analysis, and real-world observational data"],"prefix":"10.1186","volume":"24","author":[{"given":"Yalan","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosha","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"13071_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi Y, Au J, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). Journal of thoracic oncology\u202f: official publication of the International Association for the Study of Lung Cancer [J]. 2014;9:154\u201362.","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J]"},{"key":"13071_CR2","doi-asserted-by":"crossref","unstructured":"Wu YL, Planchard D, Lu S,et al.Pan-Asian adapted Clinical Practice Guidelines for the manage-ment of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS.SSO and TOS Ann Oncol. 2019;30(2):171\u2013210.","DOI":"10.1093\/annonc\/mdy554"},{"key":"13071_CR3","doi-asserted-by":"crossref","unstructured":"Liu Y, Wang J, Wu J, et al. The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study. Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033821997819.","DOI":"10.1177\/1533033821997819"},{"issue":"2","key":"13071_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.radonc.2014.07.007","volume":"112","author":"JD Zindler","year":"2014","unstructured":"Zindler JD, Slotman BJ, Lagerwaard FJ. Patterns of distant brain recurrences after radiosurgery alone for newly diagnosed brain metastases: implications for salvage therapy. Radiother Oncol. 2014;112(2):212\u20136.","journal-title":"Radiother Oncol"},{"issue":"4","key":"13071_CR5","doi-asserted-by":"publisher","first-page":"524","DOI":"10.21037\/tlcr.2019.07.03","volume":"8","author":"H Zhuang","year":"2019","unstructured":"Zhuang H, Shi S, Chang JY. Treatment modes for EGFR mutations in patients with brain metastases from non-small cell lung cancer: controversy, causes, and solutions. Transl Lung Cancer Res. 2019;8(4):524\u201331.","journal-title":"Transl Lung Cancer Res"},{"key":"13071_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial. JAMA. 2016;316:401\u20139.","journal-title":"JAMA"},{"issue":"3","key":"13071_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, et al. Spanish Lung Cancer Group in collaboration with Groupe Fran\u00e7ais de Pneumo-Canc\u00e9rologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239\u201346.","journal-title":"Lancet Oncol."},{"issue":"2","key":"13071_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"YL Wu","year":"2014","unstructured":"Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014Feb;15(2):213\u201322.","journal-title":"Lancet Oncol"},{"issue":"31","key":"13071_CR9","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.2217\/fon-2021-0549","volume":"17","author":"M Tsuboi","year":"2021","unstructured":"Tsuboi M, Weder W, Escriu C, et al. Neoadjuvant osimertinib with\/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol. 2021Nov;17(31):4045\u201355.","journal-title":"Future Oncol"},{"issue":"25","key":"13071_CR10","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, et al. North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380\u20138.","journal-title":"N Engl J Med."},{"issue":"27","key":"13071_CR11","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327\u201334.","journal-title":"J Clin Oncol"},{"issue":"3","key":"13071_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","volume":"11","author":"M Schuler","year":"2016","unstructured":"Schuler M, Wu YL, Hirsh V, et al. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. J Thorac Oncol. 2016Mar;11(3):380\u201390.","journal-title":"J Thorac Oncol"},{"key":"13071_CR13","doi-asserted-by":"publisher","first-page":"57356","DOI":"10.18632\/oncotarget.19054","volume":"8","author":"H Zheng","year":"2017","unstructured":"Zheng H, Liu QX, Hou B, et al. Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis. Oncotarget. 2017;8:57356\u201364. https:\/\/doi.org\/10.18632\/oncotarget.19054.","journal-title":"Oncotarget"},{"key":"13071_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1200\/JCO.2017.75.9589","volume":"36","author":"PD Brown","year":"2018","unstructured":"Brown PD, Ahluwalia MS, Khan OH, et al. Whole-brain radiotherapy for brain metastases: Evolution or revolution. J Clin Oncol. 2018;36:483\u201391.","journal-title":"J Clin Oncol"},{"key":"13071_CR15","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3390\/cancers11081092","volume":"11","author":"CH Chen","year":"2019","unstructured":"Chen CH, Lee HH, Chuang HY, et al. Combination of whole-brain radiotherapy with epidermal growth factor receptor tyrosine kinase inhibitors improves overall survival in EGFR-mutated non-small cell lung cancer patients with brain metastases. Cancers. 2019;11:1092.","journal-title":"Cancers"},{"issue":"9","key":"13071_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2213-2600(17)30262-X","volume":"5","author":"JJ Yang","year":"2017","unstructured":"Yang JJ, Zhou C, Huang Y, et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Lancet Respir Med. 2017Sep;5(9):707\u201316.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"13071_CR17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djac015","volume":"115","author":"XS Wang","year":"2023","unstructured":"Wang XS, Bai YF, Verma V, et al. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2023Jun 8;115(6):742\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"13071_CR18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.2147\/CMAR.S184922","volume":"11","author":"Z He","year":"2019","unstructured":"He Z, Li M, Lin J, et al. EGFRComparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced -mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study. Cancer management and research [J]. 2019;11:2129\u201338.","journal-title":"Cancer management and research [J]"},{"issue":"13","key":"13071_CR19","doi-asserted-by":"publisher","first-page":"1049855","DOI":"10.3389\/fonc.2023.1049855","volume":"9","author":"G Deng","year":"2023","unstructured":"Deng G, Tan X, Li Y, et al. Effect of EGFR-TKIs combined with craniocerebral radiotherapy on the prognosis of EGFR-mutant lung adenocarcinoma patients with brain metastasis: A propensity-score matched analysis. Front Oncol. 2023Feb;9(13):1049855.","journal-title":"Front Oncol"},{"key":"13071_CR20","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/neuonc\/noaa281","volume":"23","author":"Z Yang","year":"2021","unstructured":"Yang Z, et al. Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial. Neuro Oncol. 2021;23:967\u201378.","journal-title":"Neuro Oncol"},{"issue":"23","key":"13071_CR21","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1111\/1759-7714.14169","volume":"12","author":"Y Gu","year":"2021","unstructured":"Gu Y, Xu Y, Zhuang H, et al. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique. Thorac Cancer. 2021Dec;12(23):3157\u201368.","journal-title":"Thorac Cancer"},{"issue":"2","key":"13071_CR22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.21873\/anticanres.13195","volume":"39","author":"K Aruwatari","year":"2019","unstructured":"Aruwatari K, Ikeda T, Saeki S, et al. Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases. Anticancer Res. 2019;39(2):923\u201331.","journal-title":"Anticancer Res."},{"issue":"1","key":"13071_CR23","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1186\/s12885-019-6005-6","volume":"19","author":"Y Chen","year":"2019","unstructured":"Chen Y, Wei J, Cai J, Liu A. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis. BMC Cancer. 2019Aug 9;19(1):793.","journal-title":"BMC Cancer"},{"issue":"1","key":"13071_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/14737140.2018.1409623","volume":"18","author":"SH Li","year":"2018","unstructured":"Li SH, Liu CY, Hsu PC, et al. Response to afatinib in treatment-na\u00efve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases. Expert Rev Anticancer Ther. 2018Jan;18(1):81\u20139.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"13071_CR25","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s11596-018-1984-0","volume":"38","author":"SB Ke","year":"2018","unstructured":"Ke SB, Qiu H, Chen JM, et al. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases. Curr Med Sci. 2018Dec;38(6):1062\u20138. https:\/\/doi.org\/10.1007\/s11596-018-1984-0. (Epub 2018 Dec 7 PMID: 30536070).","journal-title":"Curr Med Sci"},{"issue":"1","key":"13071_CR26","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20176073","volume":"51","author":"RF Yang","year":"2017","unstructured":"Yang RF, Yu B, Zhang RQ, et al. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer. Braz J Med Biol Res. 2017Nov 17;51(1): e6073.","journal-title":"Braz J Med Biol Res"},{"key":"13071_CR27","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","volume":"19","author":"DN Cagney","year":"2017","unstructured":"Cagney DN, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19:1511\u201321.","journal-title":"Neuro Oncol"},{"key":"13071_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","volume":"5","author":"AS Achrol","year":"2019","unstructured":"Achrol AS, et al. Brain metastases Nature Reviews Disease Primers. 2019;5:5.","journal-title":"Brain metastases Nature Reviews Disease Primers"},{"key":"13071_CR29","doi-asserted-by":"publisher","first-page":"1297988","DOI":"10.3389\/fimmu.2023.1297988","volume":"14","author":"M Sereno","year":"2023","unstructured":"Sereno M, Hernandez de C\u00f3rdoba I, Guti\u00e9rrez-Guti\u00e9rrez G, Casado E. Brain metastases and lung cancer: molecular biology, natural history, prediction of response and efficacy of immunotherapy. Front Immunol. 2023;14:1297988.","journal-title":"Front Immunol."},{"key":"13071_CR30","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1002\/cncr.25254","volume":"116","author":"JL Hubbs","year":"2010","unstructured":"Hubbs JL, et al. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer. 2010;116:5038\u201346.","journal-title":"Cancer"},{"key":"13071_CR31","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","volume":"18","author":"PD Brown","year":"2017","unstructured":"Brown PD, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:1049\u201360.","journal-title":"Lancet Oncol"},{"issue":"1","key":"13071_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijrobp.2017.04.037","volume":"99","author":"M Yamamoto","year":"2017","unstructured":"Yamamoto M, Serizawa T, Higuchi Y, et al. A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores. Int J Radiat Oncol Biol Phys. 2017Sep 1;99(1):31\u201340.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"13071_CR33","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1200\/JCO.2005.04.6185","volume":"24","author":"D Khuntia","year":"2006","unstructured":"Khuntia D, Brown P, Li J, Mehta MP. Whole-Brain Radiotherapy in the Management of Brain Metastasis. J Clin Oncol. 2006;24:1295\u2013304.","journal-title":"J Clin Oncol"},{"key":"13071_CR34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40259-022-00556-4","volume":"36","author":"D Brazel","year":"2022","unstructured":"Brazel D, Kroening G, Nagasaka M. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options. BioDrugs. 2022;36:717\u201329.","journal-title":"BioDrugs"},{"key":"13071_CR35","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1023\/A:1008209720526","volume":"8","author":"BR Voldborg","year":"1997","unstructured":"Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 1997;8:1197\u2013206.","journal-title":"Ann Oncol"},{"key":"13071_CR36","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s12885-021-08266-w","volume":"21","author":"L Zhu","year":"2021","unstructured":"Zhu L, et al. Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study. BMC Cancer. 2021;21:511.","journal-title":"BMC Cancer"},{"key":"13071_CR37","doi-asserted-by":"publisher","first-page":"268","DOI":"10.21037\/tlcr.2019.06.12","volume":"8","author":"K Dong","year":"2019","unstructured":"Dong K, et al. EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases. Transl Lung Cancer Res. 2019;8:268\u201379.","journal-title":"Transl Lung Cancer Res"},{"key":"13071_CR38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1200\/JCO.2011.40.1174","volume":"31","author":"JW Welsh","year":"2013","unstructured":"Welsh JW, et al. Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non\u2013Small-Cell Lung Cancer. J Clin Oncol. 2013;31:895\u2013902.","journal-title":"J Clin Oncol"},{"key":"13071_CR39","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11060-014-1570-7","volume":"120","author":"L Cai","year":"2014","unstructured":"Cai L, et al. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT\/SRS\/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer. J Neurooncol. 2014;120:423\u201330.","journal-title":"J Neurooncol"},{"key":"13071_CR40","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/cam4.673","volume":"5","author":"T Jiang","year":"2016","unstructured":"Jiang T, et al. Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis. Cancer Med. 2016;5:1055\u201365.","journal-title":"Cancer Med"},{"key":"13071_CR41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","volume":"16","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, et al. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China. A Randomized Study Target Oncol. 2021;16:165\u201376.","journal-title":"A Randomized Study Target Oncol"},{"key":"13071_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","volume":"27","author":"N Colclough","year":"2021","unstructured":"Colclough N, et al. Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs. Clin Cancer Res. 2021;27:189\u2013201.","journal-title":"Clin Cancer Res"},{"key":"13071_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175571","volume":"945","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, et al. Experimental study of EGFR-TKI aumolertinib combined with ionizing radiation in EGFR mutated NSCLC brain metastases tumor. Eur J Pharmacol. 2023;945: 175571.","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"13071_CR44","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.3390\/cancers15113015","volume":"15","author":"V Tatineni","year":"2023","unstructured":"Tatineni V, O\u2019Shea PJ, Saxena S, et al. Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010\u20132019 Retrospective Cohort Study. Cancers (Basel). 2023Jun 1;15(11):3015. https:\/\/doi.org\/10.3390\/cancers15113015.","journal-title":"Cancers (Basel)"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13071-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13071-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13071-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T09:03:20Z","timestamp":1729674200000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13071-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13071"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13071-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"12 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Cancer Center of Sun Yat-sen University (Ethics Number: B2024-684-01) and the Radiotherapy Department of Hanzhong Central Hospital (Ethics Number: No. 28) and individual consent for this retrospective analysis was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1305"}}